H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $56 from $53 and keeps a Buy rating on the shares. The firm says Attruby uptake is accelerating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $42 from $37 at BMO Capital
- Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook
- BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating
- BridgeBio presents data from ATTRibute-CM
- BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential